235 related articles for article (PubMed ID: 29163493)
1. Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses.
Zhang L; Donda A
Front Immunol; 2017; 8():1417. PubMed ID: 29163493
[TBL] [Abstract][Full Text] [Related]
2. iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine.
Corgnac S; Perret R; Zhang L; Mach JP; Romero P; Donda A
J Immunother Cancer; 2014; 2(1):39. PubMed ID: 25426294
[TBL] [Abstract][Full Text] [Related]
3. Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice.
Stirnemann K; Romero JF; Baldi L; Robert B; Cesson V; Besra GS; Zauderer M; Wurm F; Corradin G; Mach JP; Macdonald HR; Donda A
J Clin Invest; 2008 Mar; 118(3):994-1005. PubMed ID: 18259610
[TBL] [Abstract][Full Text] [Related]
4. Redirecting iNKT Cell Antitumor Immunity with α-GalCer/CD1d-scFv Fusion Proteins.
Zhang L; Donda A
Methods Mol Biol; 2021; 2388():175-180. PubMed ID: 34524672
[TBL] [Abstract][Full Text] [Related]
5. Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein.
Das R; Guan P; Wiener SJ; Patel NP; Gohl TG; Evans E; Zauderer M; Nichols KE
Blood Adv; 2019 Mar; 3(5):813-824. PubMed ID: 30858151
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
[TBL] [Abstract][Full Text] [Related]
7. CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses.
Corgnac S; Perret R; Derré L; Zhang L; Stirnemann K; Zauderer M; Speiser DE; Mach JP; Romero P; Donda A
Cancer Immunol Immunother; 2013 Apr; 62(4):747-60. PubMed ID: 23242316
[TBL] [Abstract][Full Text] [Related]
8. Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodes.
Pilones KA; Aryankalayil J; Babb JS; Demaria S
J Immunother Cancer; 2014; 2(1):37. PubMed ID: 25349699
[TBL] [Abstract][Full Text] [Related]
9. CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond.
King LA; Lameris R; de Gruijl TD; van der Vliet HJ
Front Immunol; 2018; 9():1519. PubMed ID: 30013569
[TBL] [Abstract][Full Text] [Related]
10. Roles of NKT cells in cancer immunotherapy.
Bae EA; Seo H; Kim IK; Jeon I; Kang CY
Arch Pharm Res; 2019 Jul; 42(7):543-548. PubMed ID: 30859410
[TBL] [Abstract][Full Text] [Related]
11. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy.
Kharkwal SS; Johndrow CT; Veerapen N; Kharkwal H; Saavedra-Avila NA; Carreño LJ; Rothberg S; Zhang J; Garforth SJ; Jervis PJ; Zhang L; Donda A; Besra AK; Cox LR; Almo SC; Howell A; Evans EE; Zauderer M; Besra GS; Porcelli SA
Cancer Res; 2021 Apr; 81(7):1788-1801. PubMed ID: 33483371
[TBL] [Abstract][Full Text] [Related]
12. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes.
Gehrmann U; Hiltbrunner S; Georgoudaki AM; Karlsson MC; Näslund TI; Gabrielsson S
Cancer Res; 2013 Jul; 73(13):3865-76. PubMed ID: 23658368
[TBL] [Abstract][Full Text] [Related]
13. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.
Song W; van der Vliet HJ; Tai YT; Prabhala R; Wang R; Podar K; Catley L; Shammas MA; Anderson KC; Balk SP; Exley MA; Munshi NC
Clin Cancer Res; 2008 Nov; 14(21):6955-62. PubMed ID: 18980990
[TBL] [Abstract][Full Text] [Related]
14. Co-operation of α-galactosylceramide-loaded tumour cells and TLR9 agonists induce potent anti-tumour responses in a murine colon cancer model.
Dong T; Yi T; Yang M; Lin S; Li W; Xu X; Hu J; Jia L; Hong X; Niu W
Biochem J; 2016 Jan; 473(1):7-19. PubMed ID: 26450924
[TBL] [Abstract][Full Text] [Related]
15. Enhancing immunostimulatory function of human embryonic stem cell-derived dendritic cells by CD1d overexpression.
Zeng J; Shahbazi M; Wu C; Toh HC; Wang S
J Immunol; 2012 May; 188(9):4297-304. PubMed ID: 22407918
[TBL] [Abstract][Full Text] [Related]
16. Examining the role of CD1d and natural killer T cells in the development of nephritis in a genetically susceptible lupus model.
Yang JQ; Wen X; Liu H; Folayan G; Dong X; Zhou M; Van Kaer L; Singh RR
Arthritis Rheum; 2007 Apr; 56(4):1219-33. PubMed ID: 17393451
[TBL] [Abstract][Full Text] [Related]
17. NKT Cell-Driven Enhancement of Antitumor Immunity Induced by Clec9a-Targeted Tailorable Nanoemulsion.
Lam PY; Kobayashi T; Soon M; Zeng B; Dolcetti R; Leggatt G; Thomas R; Mattarollo SR
Cancer Immunol Res; 2019 Jun; 7(6):952-962. PubMed ID: 31053598
[TBL] [Abstract][Full Text] [Related]
18. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
19. Generation and sustained expansion of mouse spleen invariant NKT cell lines with preserved cytokine releasing capacity.
Molling JW; Moreno M; van der Vliet HJ; von Blomberg BM; van den Eertwegh AJ; Scheper RJ; Bontkes HJ
J Immunol Methods; 2007 Apr; 322(1-2):70-81. PubMed ID: 17343874
[TBL] [Abstract][Full Text] [Related]
20. Regeneration of invariant natural killer T (iNKT) cells: application of iPSC technology for iNKT cell-targeted tumor immunotherapy.
Aoki T; Motohashi S; Koseki H
Inflamm Regen; 2023 May; 43(1):27. PubMed ID: 37170375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]